Pediatric residents' use of jargon during counseling about newborn genetic screening results

Michael Farrell1, Lindsay Deuster, Jodi Donovan

  • 1Center for Patient Care and Outcomes Research, 8701 Watertown Plank Rd, Milwaukee, WI 53226-0509, USA. mfarrell@mcw.edu

Pediatrics
|August 5, 2008
PubMed

Insights

Pediatric residents use excessive medical jargon when discussing positive newborn screening results. Few jargon terms are explained, making genetic counseling potentially difficult for parents to understand.

Area of Science:

  • Medical Communication
  • Genetics
  • Pediatrics

Background:

  • Newborn screening tests identify infants at risk for serious genetic disorders.
  • Effective communication is crucial for parental understanding of test results and follow-up care.

Purpose of the Study:

  • To analyze the frequency and explanation of medical jargon used by pediatric residents during discussions of positive newborn screening results.
  • To assess the clarity of genetic counseling provided to parents regarding conditions like cystic fibrosis and sickle cell hemoglobinopathy.

Main Methods:

  • Analysis of recorded resident-parent encounters using standardized parents.
  • Quantitative assessment of jargon word count, explanation frequency, and time lag between jargon use and explanation.

Main Results:

  • Residents used an average of 20 unique jargon words per transcript (72.3 total words).
  • Only 17% of jargon words were explained, with an average delay of 8.2 statements.
  • High inter-rater reliability (kappa=0.92) confirmed the accuracy of the abstraction procedure.

Conclusions:

  • The high prevalence of unexplained medical jargon suggests that communication during newborn screening counseling may be overly complex for parents.
  • Improving the clarity of genetic counseling is essential for ensuring informed parental decision-making and adherence to recommended care.
Abstract

Related Concept Videos

Genetic Lingo01:11

Genetic Lingo

Overview
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...